E-resources
-
Harding, James J; Nandakumar, Subhiksha; Armenia, Joshua; Khalil, Danny N; Albano, Melanie; Ly, Michele; Shia, Jinru; Hechtman, Jaclyn F; Kundra, Ritika; El Dika, Imane; Do, Richard K; Sun, Yichao; Kingham, T Peter; D'Angelica, Michael I; Berger, Michael F; Hyman, David M; Jarnagin, William; Klimstra, David S; Janjigian, Yelena Y; Solit, David B; Schultz, Nikolaus; Abou-Alfa, Ghassan K
Clinical cancer research, 04/2019, Volume: 25, Issue: 7Journal Article
Prior molecular profiling of hepatocellular carcinoma (HCC) has identified actionable findings that may have a role in guiding therapeutic decision-making and clinical trial enrollment. We implemented prospective next-generation sequencing (NGS) in the clinic to determine whether such analyses provide predictive and/or prognostic information for HCC patients treated with contemporary systemic therapies. Matched tumor/normal DNA from patients with HCC ( = 127) were analyzed using a hybridization capture-based NGS assay designed to target 341 or more cancer-associated genes. Demographic and treatment data were prospectively collected with the goal of correlating treatment outcomes and drug response with molecular profiles. WNT/β-catenin pathway (45%) and (33%) alterations were frequent and represented mutually exclusive molecular subsets. In sorafenib-treated patients ( = 81), oncogenic PI3K-mTOR pathway alterations were associated with lower disease control rates (DCR, 8.3% vs. 40.2%), shorter median progression-free survival (PFS; 1.9 vs. 5.3 months), and shorter median overall survival (OS; 10.4 vs. 17.9 months). For patients treated with immune checkpoint inhibitors ( = 31), activating alteration WNT/β-catenin signaling were associated with lower DCR (0% vs. 53%), shorter median PFS (2.0 vs. 7.4 months), and shorter median OS (9.1 vs. 15.2 months). Twenty-four percent of patients harbored potentially actionable alterations including (8.5%) inactivating/truncating mutations, (6.3%) and (1.5%) amplifications, and missense mutations (<1%). Six percent of patients treated with systemic therapy were matched to targeted therapeutics. Linking NGS to routine clinical care has the potential to identify those patients with HCC likely to benefit from standard systemic therapies and can be used in an investigational context to match patients to genome-directed targeted therapies. .
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.